1
|
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol 2024; 166:417-418. [PMID: 38289531 DOI: 10.1007/s11060-024-04581-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Affiliation(s)
- L Gately
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
| | - C Mesía
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
| | - J M Sepúlveda
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - R Gironés
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J Fuster
- Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain
| | - W Hong
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - M Dumas
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - S Gill
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia
| | - L M Navarro
- Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain
| | - A Dowling
- Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - M A Vaz
- Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain
| | - M Alonso
- Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain
| | - Z Lwin
- Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - R Harrup
- Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia
| | - S Peralta
- Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain
| | - A Long
- Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia
| | - P Perez-Segura
- Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain
| | - E Ahern
- Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia
| | - C O Garate
- Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
| | - M Wong
- Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia
| | - R Campbell
- Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia
| | - K Cuff
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - R Jennens
- Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia
| | - O Gallego
- Medical Oncology Service, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain
| | - C Underhill
- Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia
| | | | - M Covela
- Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain
| | - A Cooper
- Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia
| | - S Brown
- Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia
| | - M Rosenthal
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - J Torres
- Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia
| | - I M Collins
- Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia
| | - P Gibbs
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - C Balana
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain
- Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| |
Collapse
|
2
|
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol 2024; 166:407-415. [PMID: 38153582 DOI: 10.1007/s11060-023-04513-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 11/15/2023] [Indexed: 12/29/2023]
Abstract
PURPOSE The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials. Standard-of-care stipulates 6 months. However, in routine care, it is often extended to 12 months, despite lacking robust supporting data. METHODS GEINO14-01 (Spain) and EX-TEM (Australia) studies enrolled glioblastoma patients without progression at the end of 6 months post-radiation temozolomide. Participants were randomised 1:1 to six additional months of temozolomide or observation. Primary endpoint was 6-month progression free survival from date of randomisation (6mPFS). Secondary endpoints included overall survival (OS) and toxicity. 204 patients were required to detect an improvement in 6mPFS from 50 to 60% (80% power). Neither study recruited sufficient patients. We performed a combined analysis of individual patient data. RESULTS 205 patients were recruited: 159 in GEINO14-01 (2014-2018) and 46 in EX-TEM (2019-2022). Median follow-up was 20.0 and 14.5 months. Baseline characteristics were balanced. There was no significant improvement in 6mPFS (57.2% vs 64.0%, OR0.75, p = 0.4), nor across any subgroups, including MGMT methylated; PFS (HR0.92, p = 0.59, median 7.8 vs 9.7 months); or OS (HR1.03, p = 0.87, median 20.1 vs 19.4 months). During treatment extension, 64% experienced any grade adverse event, mainly fatigue and gastrointestinal (both 54%). Only a minority required treatment changes: 4.5% dose delay, 7.5% dose reduction, 1.5% temozolomide discontinuation. CONCLUSION For glioblastoma patients, extending post-radiation temozolomide from 6 to 12 months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care.
Collapse
Affiliation(s)
- L Gately
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
| | - C Mesía
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain
| | - J M Sepúlveda
- Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - S Del Barco
- Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain
| | - E Pineda
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - R Gironés
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - J Fuster
- Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain
| | - W Hong
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - M Dumas
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - S Gill
- Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia
| | - L M Navarro
- Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain
| | - A Herrero
- Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain
| | - A Dowling
- Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia
| | - R de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - M A Vaz
- Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain
| | - M Alonso
- Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain
| | - Z Lwin
- Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - R Harrup
- Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia
| | - S Peralta
- Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain
| | - A Long
- Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia
| | - P Perez-Segura
- Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain
| | - E Ahern
- Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia
| | - C O Garate
- Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
| | - M Wong
- Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia
| | - R Campbell
- Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia
| | - K Cuff
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - R Jennens
- Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia
| | - O Gallego
- Medical Oncology Service, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - C Underhill
- Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia
| | | | - M Covela
- Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain
| | - A Cooper
- Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia
| | - S Brown
- Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia
| | - M Rosenthal
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - J Torres
- Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia
| | - I M Collins
- Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia
| | - P Gibbs
- Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
| | - C Balana
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain
- Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| |
Collapse
|
3
|
Morgui MS, Iriarte AR, Bergamino M, Navarro A, Arnaiz M, Palmero R, Serrahima MP, Mesía C, Padrones S, Aso S, Rodriguez JR, Navarro V, Brao I, Nadal E, Alemany FC. Recurrence pattern and its prognostic impact following definitive chemo-radiotherapy in stage III non-small cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw382.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Martinez-Garcia M, Pineda E, Del Barco S, Estival A, Verger E, Marruecos J, Gallego O, Gil M, Fuentes R, de Grigno JCBL, Lucas A, Macia M, Mesía C, Velarde J, García N, Villà S, Balana C. Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Gallego O, Estival A, Martinez-Garcia M, Pineda E, Gil M, Del Barco S, Marruecos J, Verger E, Fuentes R, Velarde J, Mesía C, Craven J, Rosell SB, Quintana C, De Huerta LP, Granell E, Gómez B, García N, Villà S, Balana C. Characteristics of gliobastomas (GBM) not resected (only biopsied) homogeneosuly treated with Stupp regimen. Results from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Estival A, Pineda E, Martinez-Garcia M, Marruecos J, Mesía C, Lucas A, Macia M, Gil M, Gallego O, Verger E, Del Barco S, Fuentes R, Craven J, García N, Villà S, Velarde J, Carrato C, Ribalta T, Arpi O, Balana C. MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Pineda E, Martinez-Garcia M, Estival A, Gil-Gil M, Del Barco S, Gallego O, Verger E, Marruecos J, Fuentes R, de Grigno JCB, Mesía C, García N, Alameda F, Velarde J, Pujol T, Oleaga L, Carrato C, Capellades J, Villà S, Balana C. Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw367.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011; 71:191-8. [PMID: 20627363 DOI: 10.1016/j.lungcan.2010.05.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Revised: 03/30/2010] [Accepted: 05/02/2010] [Indexed: 10/19/2022]
Abstract
UNLABELLED New therapeutic approaches are being developed based on the findings that several genetic abnormalities underlying NSCLC could influence chemosensitivity. In this study, we assessed whether the presence of polymorphisms in ERCC1, XPD, RRM1 and MDR1 genes can affect the efficacy and the tolerability of cisplatin and vinorelbine in NSCLC patients. MATERIAL AND METHODS Eligible patients had histological confirmed stage IV or IIIB (with malignant pleural effusion) non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy; World Health Organization performance status (PS) 0-1. Patients received intravenous doses of vinorelbine 25 mg/m² on day 1 and 8 and cisplatin 75 mg/m² on day 1, every 21 days, for a maximum of eight cycles. RESULTS 94 patients were included. Median age was 61 years; 84% were male; WHO performance status (PS) was 0 in 24%; and 88% of patients had stage IV disease. The median number of cycles was 6. Overall median survival was 10.92 months (95% CI 9.0-12.9). Overall median time to progression was 5.89 months (95% CI 5.2-6.6). Results of the multivariate analysis for time to progression showed that ECOG 0 (hazard ratio [HR] ECOG 1 vs. ECOG 0, 1.74; p=0.036), MDR13435CC (HR CT vs. CC, 2.01; p=0.017; HR TT vs. CC, 1.54; p=0.22), and decreasing age (HR of age, 0.97; p=0.016) were the most powerful prognostic factors significantly related to lower risk of progression. Whereas ECOG 0 was the only prognostic factor for survival (HR ECOG 1 vs. ECOG 0, 3.02; p=0.001). There was no significant association between any of the SNPs analysed and the occurrence of vinorelbine and cisplatin-related toxicity. CONCLUSION In our results, the most important prognostic factors associated with lower risk of progression were MDR1 3435 CC genotype, PS 0 and younger age.
Collapse
Affiliation(s)
- N Viñolas
- Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Alberola V, Gallego O, López-Vivanco G, Mesía C, Oramas J, Trigo JM, Virizuela JA, Camps C, Regueiro P, Massutí B. Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1st, 2nd and 3rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p<0.001) and cough was 24.7% vs 8.8 % (p<0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p<0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Alberola
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - O. Gallego
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - G. López-Vivanco
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - C. Mesía
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. Oramas
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. M. Trigo
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - J. A. Virizuela
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - C. Camps
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - P. Regueiro
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| | - B. Massutí
- Hospital Universitari Arnau de Vilanova, Valencia, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Hospital Cruces, Barakaldo, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Hospital Virgen de la Victoria, Málaga, Spain; Hospital Universitario Virgen Macarena, Sevilla, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Roche Farma, S.A., Madrid, Spain; Hospital General Universitario de Alicante, Alicante, Spain
| |
Collapse
|
10
|
Blanco R, Solé J, Nogué M, Montesinos J, Gallardo E, Vadell C, Mesía C, Algara M, Terrasa J. PD-039 Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation (CCR) with biweekly gemcitabine in unresectable stage III non small cell lung cancer (NSCLC): Final results of a phase II study. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80371-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
11
|
Blanco R, Solé J, Nogué M, Montesinos J, Gallardo E, Vadell C, Mesía C, Algara M, Terrassa J. Phase II multicentric study of concurrent chemoradiation (CCR) with biweekly gemcitabine after induction chemotherapy with cisplatin and gemcitabine in unresectable stage III non small cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Blanco
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - J. Solé
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - M. Nogué
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - J. Montesinos
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - E. Gallardo
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - C. Vadell
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - C. Mesía
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - M. Algara
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| | - J. Terrassa
- Hospital de Terassa, Terrassa, Spain; Hospital General de Catalunya, St. Cugat del Vallès, Spain; Hospital General de Vic, Vic, Spain; Consorci Hospitalari del Parc Taulí, Sabadell, Spain; Clínica Miramar, Baleares, Spain; Hospital del Mar, Barcelona, Spain; Hospital de la Esperança, Barcelona, Spain; Hospital son Dureta, Palma de Mallorca, Spain
| |
Collapse
|